A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension

References

• Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet. 2017 Nov 11;390(10108):2183–2193.
   PubMed Web of Science ®Google Scholar
• Stein JD, Khawaja AP, Weizer JS. Glaucoma in adults-screening, diagnosis, and management: a review. JAMA. 2021 Jan 12;325(2):164–174.
   PubMed Web of Science ®Google Scholar
• Quigley HA. 21st century glaucoma care. Eye (Lond). 2019;33(2):254–260.
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CAB, Schouten JSAG, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005 Jul;112(7):1177–1185.
   PubMed Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007 Jan;6(1):45–52.
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 5th ed ed. Savona Italy: GECA Srl; 2020.
   Google Scholar
• Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther.2013 May;29(4):382–389.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Katsanos A, Quaranta L, et al. Twenty-four hour efficacy of glaucoma medications. Prog Brain Res. 2015;221:297–318.
   PubMed Web of Science ®Google Scholar
• Tang W, Zhang F, Liu K, et al. Efficacy and safety of prostaglandin analogues in primary open-angle glaucoma or ocular hypertension patients: a meta-analysis. Medicine (Baltimore). 2019 Jul;98(30):e16597.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Bozkurt B, et al. 24-h efficacy of glaucoma treatment options. Adv Ther. 2016 Apr;33(4):481–517.
   PubMed Web of Science ®Google Scholar
• Katsanos A, Dastiridou AI. Pharmacotherapy of glaucoma: new opportunities, old challenges. Expert Opin Pharmacother. 2017;18(13):1289–1290.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul;29(4):312–334.
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013 Dec;22(9):730–735.
   PubMed Web of Science ®Google Scholar
• Dubrulle P, Labbe A, Brasnu E, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018 Dec;27(12):1105–1111.
   PubMed Web of Science ®Google Scholar
• Konstas AG, Labbé A, Katsanos A, et al. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opin Drug Saf. 2021 Apr;20(4):453–466.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A, Boboridis KG, et al. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs 2018 Jan;78(1):39–64.
   PubMed Web of Science ®Google Scholar
• Nordmann J-P, Auzanneau N, Ricard S, et al. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 2003 Dec 10;1:75.
   PubMedGoogle Scholar
• Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008 Nov;53(Suppl1):S57–68.
   PubMedGoogle Scholar
• Brandt JD. Does benzalkonium chloride cause cataract? Arch Ophthalmol. 2003 Jun;121(6):892–893.
   PubMedGoogle Scholar
• Goto Y. Human lens epithelial cell damage and stimulation of their secretion of chemical mediators by benzalkonium chloride rather than latanoprost and timolol. Arch Ophthalmol. 2003 Jun;121(6):835–839.
   PubMedGoogle Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008 Nov;53(Suppl1):S69–84.
   PubMedGoogle Scholar
• Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol. 2002 Aug;47(Suppl 1):S2–5.
   PubMedGoogle Scholar
• Camras CB, Alm A. Initial clinical studies with prostaglandins and their analogues. Surv Ophthalmol. 1997 Feb;41(Suppl 2):S61–68.
   PubMedGoogle Scholar
• Toris CB, Gabelt BT, Kaufman PL. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53(Suppl1):S107–120.
   PubMedGoogle Scholar
• Alm A. Latanoprost in the treatment of glaucoma. Clin Ophthalmol. 2014;8:1967–1985.
   PubMedGoogle Scholar
• Cracknell KPB, Grierson I. Prostaglandin analogues in the anterior eye: their pressure lowering action and side effects. Exp Eye Res. 2009 Apr;88(4):786–791.
   PubMed Web of Science ®Google Scholar
• Dams I, Wasyluk J, Prost M, et al. Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies. Prostaglandins Other Lipid Mediat. 2013 Aug;104–105:109–121.
   PubMed Web of Science ®Google Scholar
• Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008 Nov;53(Suppl1):S93–105.
   PubMedGoogle Scholar
• Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012 Nov;26(11):1465–1472.
   PubMed Web of Science ®Google Scholar
• Jayaprakasam A, Ghazi-Nouri S. Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues. Orbit. 2010 Dec;29(6):357–359.
   PubMedGoogle Scholar
• Park J, Cho HK, Moon J-I. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011 Jan;55(1):22–27.
   PubMed Web of Science ®Google Scholar
• Shah M, Lee G, Lefebvre DR, et al. A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013;8(5):e61638.
   PubMed Web of Science ®Google Scholar
• Kucukevcilioglu M, Bayer A, Uysal Y, et al. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Exp Ophthalmol. 2014 Mar;42(2):126–131.
   PubMed Web of Science ®Google Scholar
• Honrubia F, García-Sánchez J, Polo V, et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009 Mar;93(3):316–321.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Kozobolis VP, Katsimpris IE, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007 Apr;114(4):653–657.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther. 2000 Feb;22(2):167–208.
   PubMed Web of Science ®Google Scholar
• Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch. Expert Opin Pharmacother. 2012 Apr;13(5):723–745.
   PubMedGoogle Scholar
• Inoue K, Wakakura M, Inoue J, et al. [Adverse reaction after use of latanoprost in Japanese glaucoma patients]. Nippon Ganka Gakkai Zasshi. 2006 Aug;110(8):581–587.
   PubMedGoogle Scholar
• Inoue K, Shiokawa M, Wakakura M, et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013 Nov;22(8):626–631.
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu W-P, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003 May;135(5):688–703.
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao YJ, Chew PTK, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother. 2014 Dec;48(12):1585–1593.
   PubMed Web of Science ®Google Scholar
• Daka Q, Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014 Oct;55(5):468–480.
   PubMed Web of Science ®Google Scholar
• Yang X-T. Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a meta-analysis. Int J Ophthalmol. 2020;13(3):474–480.
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002 Aug;47(Suppl 1):S129–132.
   PubMedGoogle Scholar
• Quaranta L, Biagioli E, Riva I, et al. The glaucoma italian pediatric study (GIPSy): 3-year results. J Glaucoma. 2018;27(10):856–863.
   PubMed Web of Science ®Google Scholar
• Maeda-Chubachi T, Chi-Burris K, Simons BD, et al. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study. Ophthalmology. 2011 Oct;118(10):2014–2021.
   PubMed Web of Science ®Google Scholar
• Chen R, Yang K, Zheng Z, et al. Meta-analysis of the efficacy and safety of latanoprost monotherapy in patients with angle-closure glaucoma. J Glaucoma. 2016 Mar;25(3):e134–144.
   PubMed Web of Science ®Google Scholar
• Sun pharmaceutical industries, Ltd. Xelpros prescribing information.
   Google Scholar
• Halder A, Khopade AJ. Physiochemical properties and cytotoxicity of a benzalkonium chloride-free, micellar emulsion ophthalmic formulation of latanoprost. Clin Ophthalmol. 2020;14:3057–3064.
   PubMed Web of Science ®Google Scholar
• Sanford M. Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension. Clin Drug Investig. 2014 Jul;34(7):521–528.
   PubMed Web of Science ®Google Scholar
• El Ameen A, Vandermeer G, Khanna RK, et al. Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues. Eur J Ophthalmol. 2019 Nov;29(6):645–653.
   PubMed Web of Science ®Google Scholar
• Harasymowycz P, Hutnik C, Rouland J-F, et al. Preserved versus preservative-free latanoprost for the treatment of glaucoma and ocular hypertension: a post hoc pooled analysis. Adv Ther. 2021 Jun;38(6):3019–3031.
   PubMed Web of Science ®Google Scholar
• Alcon Laboratories Inc. TRAVATAN (R) prescribing information (revised 7/2010)
   Google Scholar
• Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001 Oct;132(4):472–484.
   PubMed Web of Science ®Google Scholar
• Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001 Oct;10(5):414–422.
   PubMed Web of Science ®Google Scholar
• Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002 May;109(5):998–1008.
   PubMed Web of Science ®Google Scholar
• Guenoun J-M, Baudouin C, Rat P, et al. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2444–2450.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Riancho L, Warnet J-M BF. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4123–4128.
   PubMed Web of Science ®Google Scholar
• Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006 Aug;23(4):511–519.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Cavanagh HD, Lakshman N, et al. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006 Oct;23(5):663–671.
   PubMed Web of Science ®Google Scholar
• Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008 Apr;27(3):339–343.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007 Jan;16(1):98–103.
   PubMed Web of Science ®Google Scholar
• Aihara M, Oshima H, Araie M. EXTraKT study group. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface – a multicentre randomized single-masked study. Acta Ophthalmol. 2013 Feb;91(1):e7–14.
   PubMed Web of Science ®Google Scholar
• Aihara M, Ikeda Y, Mizoue S, et al. Effect of switching to travoprost preserved with sofzia in glaucoma patients with chronic superficial punctate keratitis while receiving BAK-preserved latanoprost. J Glaucoma. 2016;25(6):e610–614.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Nanno M, Kimura T, et al. Effects of switching to SofZia-preserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol. 2010 Jan;54(1):7–14.
   PubMed Web of Science ®Google Scholar
• Kanamoto T, Kiuchi Y, Suehiro T, et al. Efficacy and safety of topical travoprost with sofzia preservative for Japanese glaucoma patients. Hiroshima J Med Sci. 2010 Dec;59(4):71–75.
   PubMedGoogle Scholar
• Mizoue S, Nakano T, Fuse N, et al. Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects. Clin Ophthalmol. 2014;8:347–354.
   PubMedGoogle Scholar
• Kanamoto T, Kiuchi Y, Tanito M, et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015 Apr;31(3):156–164.
   PubMed Web of Science ®Google Scholar
• Rahmatnejad K, Rapuano CJ, Ichhpujani P, et al. The effects of latanoprost with benzalkonium chloride versus travoprost with SofZia on the ocular surface. Eye Contact Lens. 2018 Nov;44(Suppl 2):S93–8.
   PubMedGoogle Scholar
• Brignole-Baudouin F, Riancho L, Liang H, et al. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res. 2011 Nov;36(11):979–988.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Usui T, Yokoo S, et al. Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets. Invest Ophthalmol Vis Sci. 2012 Aug 3;53(9):5154–5160.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Petroll WM. Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents. Adv Ther. 2012 Oct;29(10):874–888.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Jun RM, Cho MS, et al. Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes. Cutan Ocul Toxicol. 2015;34(3):195–202.
   PubMed Web of Science ®Google Scholar
• Marsovszky L, Resch MD, Visontai Z, et al. Confocal microscopy of epithelial and langerhans cells of the cornea in patients using travoprost drops containing two different preservatives. Pathol Oncol Res. 2014 Jul;20(3):741–746.
   PubMed Web of Science ®Google Scholar
• Ammar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther. 2010 Nov;27(11):837–845.
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012 Feb;22(1):34–44.
   PubMed Web of Science ®Google Scholar
• García-Feijoo J, Muñoz-Negrete FJ, Hubatsch DA, et al. Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clin Ophthalmol. 2016;10:2085–2091.
   PubMed Web of Science ®Google Scholar
• Peace JH, Ahlberg P, Wagner M, et al. Polyquaternium-1-Preserved travoprost 0.003% or benzalkonium chloride-preserved travoprost 0.004% for glaucoma and ocular hypertension. Am J Ophthalmol. 2015 Aug;160(2):266–274.e1.
   PubMed Web of Science ®Google Scholar
• Riva I, Katsanos A, Floriani I, et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014 Nov;23(8):535–540.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Riva I, Katsanos A, et al. Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure. Clin Ophthalmol. 2015;9:633–643.
   PubMed Web of Science ®Google Scholar
• Alm A. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol. 2004 Jul;122(7):957–965.
   PubMedGoogle Scholar
• Li N, Chen X, Zhou Y, et al. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Experiment Ophthalmol. 2006 Nov;34(8):755–764.
   PubMed Web of Science ®Google Scholar
• Wand M, Gaudio AR. Cystoid macular oedema associated with ocular hypotensive lipids. Am J Ophthalmol. 2002 Mar;133(3):403–405.
   PubMed Web of Science ®Google Scholar
• Arcieri ES. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005 Feb;123(2):186–192.
   PubMedGoogle Scholar
• Holló G, Aung T, Cantor LB, et al. Cystoid macular oedema related to cataract surgery and topical prostaglandin analogs: mechanism, diagnosis, and management. Surv Ophthalmol. 2020 Oct;65(5):496–512.
   PubMed Web of Science ®Google Scholar
• Faulkner WJ. Acute anterior uveitis and corneal oedema associated with travoprost. Arch Ophthalmol. 2003 Jul;121(7):1054–1055.
   PubMedGoogle Scholar
• Suominen S, Välimäki J. Bilateral anterior uveitis associated with travoprost. Acta Ophthalmol Scand. 2006 Apr;84(2):275–276.
   PubMedGoogle Scholar
• Aydin S, Ozcura F. Corneal ooedema and acute anterior uveitis after two doses of travoprost. Acta Ophthalmol Scand. 2007 Sep;85(6):693–694.
   PubMedGoogle Scholar
• Chiam P. Travoprost induced granulomatous anterior uveitis. Case Rep Ophthalmol Med. 2011;2011:507073.
   PubMedGoogle Scholar
• Villegas VM, Díaz L, Izquierdo NJ. Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report. P R Health Sci J. 2008 Dec;27(4):348–349.
   PubMed Web of Science ®Google Scholar
• Wendel C, Zakrzewski H, Carleton B, et al. Association of postoperative topical prostaglandin analog or beta-blocker use and incidence of pseudophakic cystoid macular oedema. J Glaucoma. 2018;27(5):402–406.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Shen X, Yu J, et al. The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea 2011 Aug;30(8):861–864.
   PubMed Web of Science ®Google Scholar
• Schlote T, Tzamalis A, Kynigopoulos M. Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients. J Ocul Pharmacol Ther. 2009 Oct;25(5):459–462.
   PubMed Web of Science ®Google Scholar
• Harasymowycz PJ, Papamatheakis DG, Ennis M, et al. Travoprost Central Corneal Thickness Study Group. Relationship between Travoprost and Central Corneal Thickness in Ocular Hypertension and Open-angle Glaucoma Cornea. 2007 Jan;26(1):34–41.
   Google Scholar
• Fini ME, Girard MT. Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci. 1990 Sep;31(9):1779–1788.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yanai R, Lu Y, et al. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma. 2006 Jun;15(3):255–259.
   PubMed Web of Science ®Google Scholar
• Sánchez-Barahona C, Bolívar G, Katsanos A, et al. Latanoprost treatment differentially affects intraocular pressure readings obtained with three different tonometers. Acta Ophthalmol. 2019 Dec;97(8):e1112–5.
   PubMed Web of Science ®Google Scholar
• Bolívar G, Sánchez-Barahona C, Teus M, et al. Effect of topical prostaglandin analogues on corneal hysteresis. Acta Ophthalmol. 2015 Sep;93(6):e495–498.
   PubMed Web of Science ®Google Scholar
• Li J, Wang X, Xu G, et al. Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose. Exp Ther Med. 2020 Nov;20(5):24.
   PubMed Web of Science ®Google Scholar
• Arranz-Marquez E, Teus MA. Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801–808.
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45(Suppl 4):S347–351.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. LUMIGAN prescribing information. 2014.
   Google Scholar
• Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002 Oct;120(10):1286–1293.
   PubMed Web of Science ®Google Scholar
• Day DG, Walters TR, Schwartz GF, et al. Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. Br J Ophthalmol. 2013 Aug;97(8):989–993.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007 Dec;30(12):2360–2364.
   PubMed Web of Science ®Google Scholar
• Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010 Apr;149(4):661–671.
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology 2016 Jan;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005 Feb;112(2):262–266.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AGP, Nelson LA, et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008 Jul;115(7):1117–1122.e1.
   PubMed Web of Science ®Google Scholar
• Holló G, Katsanos A. Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. Expert Opin Drug Saf. 2015 Apr;14(4):609–617.
   PubMed Web of Science ®Google Scholar
• Papadia M, Bagnis A, Scotto R, et al. Tafluprost for glaucoma. Expert Opin Pharmacother. 2011 Oct;12(15):2393–2401.
   PubMedGoogle Scholar
• Sakata R, Shirato S, Miyata K, et al. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014 Mar;58(2):212–217.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Fukuchi T, Togano T, et al. Eyelid and eyelash changes due to prostaglandin analog therapy in unilateral treatment cases. Jpn J Ophthalmol. 2013 Mar;57(2):172–178.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Teranishi S, Sagara T, et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis. J Glaucoma. 2015 Aug;24(6):e145–150.
   PubMed Web of Science ®Google Scholar
• Kumagami T, Wakiyama H, Kusano M, et al. Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther. 2014 May;30(4):340–345.
   PubMed Web of Science ®Google Scholar
• Chabi A, Varma R, Tsai JC, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012 Jun;153(6):1187–1196.
   PubMed Web of Science ®Google Scholar
• Milla E, Stirbu O, Rey A, et al. Spanish multicenter tafluprost tolerability study. Br J Ophthalmol. 2012 Jun;96(6):826–831.
   PubMed Web of Science ®Google Scholar
• Lanzl I, Hamacher T, Rosbach K, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clin Ophthalmol. 2013;7:901–910.
   PubMedGoogle Scholar
• Uusitalo H, Egorov E, Kaarniranta K, et al. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454.
   PubMed Web of Science ®Google Scholar
• Konstas A-G, Boboridis KG, Kapis P, et al. 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients Insufficiently controlled with preserved latanoprost monotherapy. Adv Ther. 2017 Jan;34(1):221–235.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010 Feb;88(1):12–19.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013 Dec;97(12):1510–1515.
   PubMed Web of Science ®Google Scholar
• Traverso CE, Ropo A, Papadia M, et al. A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. J Ocul Pharmacol Ther. 2010 Feb;26(1):97–104.
   PubMed Web of Science ®Google Scholar
• Krauss AHP, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250–255.
   PubMed Web of Science ®Google Scholar
• Araie M, Sforzolini BS, Vittitow J, et al. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther. 2015 Nov;32(11):1128–1139.
   PubMed Web of Science ®Google Scholar
• Kawase K, Vittitow JL, Weinreb RN, et al. Efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the jupiter study. Adv Ther. 2016;33(9):1612–1627.
   PubMed Web of Science ®Google Scholar
• Latanoprost-Induced Iris Pigmentation Study Group. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol. 2006 Apr;50(2):96–99
   PubMed Web of Science ®Google Scholar
• Chiba T, Kashiwagi K, Ishijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004 Apr;48(2):141–147.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015 Jun;99(6):738–745.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, et al. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016 May;123(5):965–973.
   PubMed Web of Science ®Google Scholar
• Zhang WY. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2001 Aug;85(8):983–990.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016 Aug;168:250–259.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Liebmann JM, Martin KR, et al. 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7–15.
   PubMed Web of Science ®Google Scholar
• Impagnatiello F, Toris CB, Batugo M, et al. Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6558–6564.
   PubMed Web of Science ®Google Scholar
• Impagnatiello F, Bastia E, Almirante N, et al. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma. Br J Pharmacol. 2019;176(8):1079–1089.
   PubMed Web of Science ®Google Scholar
• Schachar RA, Raber S, Courtney R, et al. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809–817.
   PubMed Web of Science ®Google Scholar
• Santen Pharmaceutical Co LTD. EYBELIS Drug Information Sheet. 2018. [cited 2021 Oct 24]. Available from: https://www.rad-ar.or.jp/siori/english/kekka.cgi?n=40664
   Google Scholar
• Aihara M, Lu F, Kawata H, et al. Six-month efficacy and safety outcomes of a novel selective EP2 agonist omidenepag isopropyl: the RENGE study (phase 3). Invest Ophthalmol Vis Sci. 2018;59(9):1229.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Phase 2, randomized, dose-finding studies of omidenepag isopropyl, a selective EP2 agonist, in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2019;28(5):375–385.
   PubMed Web of Science ®Google Scholar
• Aihara M, Lu F, Kawata H, et al. Omidenepag isopropyl versus latanoprost in primary open-angle glaucoma and ocular hypertension: the phase 3 AYAME study. Am J Ophthalmol. 2020 Dec;220:53–63.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Taniguchi T, Inazumi T, et al. Effects of the selective EP2 receptor agonist omidenepag on adipocyte differentiation in 3T3-L1 cells. J Ocul Pharmacol Ther. 2020 Apr;36(3):162–169.
   PubMed Web of Science ®Google Scholar
• Hikage F, Ida Y, Ouchi Y, et al. Omidenepag, a selective, prostanoid EP2 agonist, does not suppress adipogenesis in 3D organoids of human orbital fibroblasts. Transl Vis Sci Technol. 2021 Apr 1;10(4):6.
   PubMed Web of Science ®Google Scholar
• Oogi S, Nakakura S, Terao E, et al. Study of changes in prostaglandin-associated periorbital syndrome after switch from conventional prostaglandin F2alfa to omidenepag isopropyl. Cureus. 2020 Aug 27;12(8):e10064.
   PubMed Web of Science ®Google Scholar
• Sakata R, Fujishiro T, Saito H, et al. Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis. Jpn J Ophthalmol. 2021 Sep;65(5):591–597.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of three formulations of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution - study results - clinicaltrials.gov [Internet]. [cited 2020 Dec 27]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01001195
   Google Scholar
• Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol. 2016 Jun;100(6):843–847.
   PubMed Web of Science ®Google Scholar